PubMed COVID-19 Clinical Care
1821 - 1830 of 3573 results found
Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir combination therapy in patients with high-risk factors infected with Omicron (B.1.1.529): A multi-arm single-center, open-label, randomized controlled trial
Description
CONCLUSION: For patients with severe COVID-19, HSBD exhibits similar efficacy to Paxlovid, while combination therapy is more likely to increase the curative efficacy of Omicron variant than monotherapies, with few serious adverse events.
Erythema Nodosum Induced by the Pfizer- BioNTech Vaccine
Description
A 42-year-old man presented with a painful nodular dermatitis with 38.5°C fever and joint pain, which started overnight. The patient had taken the first dose of Pfizer-BioNTech (Comirnaty, INN-COVID-19 mRNA) vaccine 8 days ago. He denied any kind of
Eosinophilic Granulomatosis with Polyangiitis after mRNA-1273 SARS-CoV-2 Vaccine
Description
During one of the worst global health crises, millions of people were vaccinated against SARS-CoV-2. In rare cases, new onset systemic inflammatory diseases were reported with temporal coincidence to the vaccination. We describe a case of severe
Exigency of Plant-Based Vaccine against COVID-19 Emergence as Pandemic Preparedness
Description
After two years since the declaration of COVID-19 as a pandemic by the World Health Organization (WHO), more than six million deaths have occurred due to SARS-CoV-2, leading to an unprecedented disruption of the global economy. Fortunately, within a
Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters
Description
The successful development of a chemoprophylaxis against SARS-CoV-2 could provide a tool for infection prevention that is implementable alongside vaccination programmes. Nafamostat is a serine protease inhibitor that inhibits SARS-CoV-2 entry in
Exploring missed opportunities for influenza vaccination and influenza vaccine co-administration patterns among Italian older adults: a retrospective cohort study
Description
CONCLUSIONS: A sizeable proportion of older adults who received other recommended vaccines during the last influenza season did not receive SIV. This share of missed opportunities, which are subject to some social inequalities, may be addressed by
Efficacy, Pharmacokinetics, and Toxicity Profiles of a Broad Anti-SARS-CoV-2 Neutralizing Antibody
Description
We recently reported the isolation and characterization of an anti-SARS-CoV-2 antibody, called IgG-A7, that protects transgenic mice expressing the human angiotensin-converting enzyme 2 (hACE-2) from an infection with SARS-CoV-2 Wuhan. We show here
Effects of the COVID-19 pandemic on trauma-related emergency medical service in older people: a retrospective cohort study
Description
CONCLUSIONS: The high prevalence rate of geriatric traumas can be primarily attributed to their physical problems and no control over movements caused by old age, as well as unsafe living conditions. To address these issues, it is suggested that
Efficiency of Chitosan Nanocarriers in Vaccinology for Mucosal Immunization
Description
The mucosal barrier constitutes a huge surface area, close to 40 m² in humans, located mostly in the respiratory, gastrointestinal and urogenital tracts and ocular cavities. It plays a crucial role in tissue interactions with the microbiome, dietary
